CUSIP
No. 759757 88 3
|
13D
|
Page
2 of 10
|
1.
|
Names
of Reporting Persons
Seamus
Lagan
|
2.
|
Check
the Appropriate Box if a Member of a Group
(a)
[ ]
(b)
[ ]
|
3.
|
SEC
Use Only
|
4.
|
Source
of Funds (See Instructions)
OO
|
5.
|
Check
Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ]
|
6.
|
Citizenship
Or Place Of Organization
Ireland
|
Number
Of
Shares
Beneficially
Owned
By
Each
Reporting
Person
With
|
7.
|
Sole
Voting Power
11
|
8.
|
Shared
Voting Power
-0-
|
9.
|
Sole
Dispositive Power
11
|
10.
|
Shared
Dispositive Power
-0-
|
11.
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
11
|
12.
|
Check
Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [X]
|
13.
|
Percent
of Class Represented by Amount in Row (11)
0.0%
|
14.
|
Type
of Reporting Person
IN
|
CUSIP
No. 759757 88 3
|
13D
|
Page
3 of 10
|
1.
|
Names
of Reporting Persons
Alcimede
LLC
|
2.
|
Check
the Appropriate Box if a Member of a Group
(a)
[ ]
(b)
[ ]
|
3.
|
SEC
Use Only
|
4.
|
Source
of Funds (See Instructions)
OO
|
5.
|
Check
Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ]
|
6.
|
Citizenship
Or Place Of Organization
Delaware
|
Number
Of
Shares
Beneficially
Owned By
Each
Reporting
Person
With
|
7.
|
Sole
Voting Power
-0-
|
8.
|
Shared
Voting Power
-0-
|
9.
|
Sole
Dispositive Power
-0-
|
10.
|
Shared
Dispositive Power
-0-
|
11.
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
-0-
|
12.
|
Check
Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [X]
|
13.
|
Percent
of Class Represented by Amount in Row (11)
0.0%
|
14.
|
Type
of Reporting Person
OO
|
CUSIP
No. 759757 88 3
|
13D
|
Page
4 of 10
|
1.
|
Names
of Reporting Persons
Epizon
Ltd.
|
2.
|
Check
the Appropriate Box if a Member of a Group
(a)
[ ]
(b)
[ ]
|
3.
|
SEC
Use Only
|
4.
|
Source
of Funds (See Instructions)
OO
|
5.
|
Check
Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ]
|
6.
|
Citizenship
Or Place Of Organization
Commonwealth
of the Bahamas
|
Number
Of
Shares
Beneficially
Owned By
Each
Reporting
Person
With
|
7.
|
Sole
Voting Power
-0-
|
8.
|
Shared
Voting Power
-0-
|
9.
|
Sole
Dispositive Power
-0-
|
10.
|
Shared
Dispositive Power
-0-
|
11.
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
-0-
|
12.
|
Check
Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [X]
|
13.
|
Percent
of Class Represented by Amount in Row (11)
0.0%
|
14.
|
Type
of Reporting Person
OO
|
CUSIP
No. 759757 88 3
|
13D
|
Page
5 of 10
|
1.
|
Names
of Reporting Persons
P.
Wilhelm F. Toothe, Trustee of The Shanoven Trust
|
2.
|
Check
the Appropriate Box if a Member of a Group
(a)
[ ]
(b)
[ ]
|
3.
|
SEC
Use Only
|
4.
|
Source
of Funds (See Instructions)
OO
|
5.
|
Check
Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ]
|
6.
|
Citizenship
Or Place Of Organization
Commonwealth
of the Bahamas
|
Number
Of
Shares Beneficially Owned By
Each
Reporting
Person
With
|
7.
|
Sole
Voting Power
-0-
|
8.
|
Shared
Voting Power
-0-
|
9.
|
Sole
Dispositive Power
-0-
|
10.
|
Shared
Dispositive Power
-0-
|
11.
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
-0-
|
12.
|
Check
Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [X]
|
13.
|
Percent
of Class Represented by Amount in Row (11)
0.0%
|
14.
|
Type
of Reporting Person
OO
|
CUSIP
No. 759757 88 3
|
13D
|
Page
6 of 10
|
1.
|
Names
of Reporting Persons
The
Shanoven Trust
|
2.
|
Check
the Appropriate Box if a Member of a Group
(a)
[ ]
(b)
[ ]
|
3.
|
SEC
Use Only
|
4.
|
Source
of Funds (See Instructions)
OO
|
5.
|
Check
Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ]
|
6.
|
Citizenship
Or Place Of Organization
Commonwealth
of the Bahamas
|
Number
Of Shares Beneficially Owned
By Each Reporting
Person
With
|
7.
|
Sole
Voting Power
-0-
|
8.
|
Shared
Voting Power
-0-
|
9.
|
Sole
Dispositive Power
-0-
|
10.
|
Shared
Dispositive Power
-0-
|
11.
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
-0-
|
12.
|
Check
Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [X]
|
13.
|
Percent
of Class Represented by Amount in Row (11)
0.0%
|
14.
|
Type
of Reporting Person
OO
|
CUSIP
No. 759757 88 3
|
13D
|
Page
7 of 10
|
Item 1.
|
Security and Issuer
|
This
Amendment No. 7 to Schedule 13D amends the Statement on Schedule 13D, dated November 2, 2015, as previously amended by Amendments
No. 1, No. 2, No. 3, No. 4, No. 5 and No. 6 to Schedule 13D, with respect to the Common Stock, $0.0001 par value per share (the
“Shares”), of Rennova Health, Inc., a Delaware corporation (the “Issuer”), filed by: Seamus Lagan; Alcimede
LLC, a Delaware limited liability company (“Alcimede”); Epizon Ltd. (“Epizon”), a Bahamian international
business corporation, which is wholly-owned by The Shanoven Trust, of which P. Wilhelm F. Toothe serves as the trustee; P. Wilhelm
F. Toothe, as trustee of The Shanoven Trust; and The Shanoven Trust. Except as expressly amended below, Schedule 13D, dated November
2, 2015, as previously amended, remains in effect. All share numbers stated herein prior to July 31, 2020 do not reflect the
1-for-10,000 reverse stock split of the Shares that was effective at 5:00 p.m., Eastern time, on July 31, 2020.
Item 3.
|
Source and Amount of Funds or Other Consideration
|
Item
3 is hereby amended, and this Amendment No. 7 to Schedule 13D is being filed, to include the following:
(i)
the exchange on December 23, 2019 by Alcimede of the 250,000 shares of the Issuer’s Series J Convertible Preferred Stock
owned by Alcimede for 250,000 shares of the Issuer’s Series K Convertible Preferred
Stock (the “Series K Preferred Stock”). Alcimede owned all of the Series K Preferred Stock. Each share of Series K
Preferred Stock was convertible at any time at the option of the holder, into that number of Shares determined by dividing the
stated value (which was $1.00 per share) of such share of Series K Preferred Stock, plus all accrued and unpaid dividends thereon,
by the conversion price. The conversion price was equal to the average closing price of the Shares on the 10 trading days immediately
prior to the conversion date. As of December 23, 2019, the shares of Series K Preferred Stock owned by Alcimede were convertible
into 2,500,000,000 Shares.
Each
holder of the Series K Preferred Stock was entitled to vote on all matters submitted to a vote of the holder of the Shares. Each
share of Series K Preferred Stock was entitled to the whole number of votes equal to the number of Shares into which it
was then convertible. The Series K Preferred Stock could vote with the Shares as if they were a single class of securities.
(ii)
the exchange on May 5, 2020 by Alcimede of the 250,000 shares of Series K Preferred Stock owned by Alcimede for 250,000 shares
of the Issuer’s Series L Convertible Preferred Stock (the “Series L Preferred Stock”). Alcimede owns all of
the Series L Preferred Stock. The shares of Series L Preferred Stock are not convertible into Shares prior to December 1, 2020.
From and after December 1, 2020, each share of Series L Preferred Stock is convertible, at the option of the holder, into that
number of Shares determined by dividing the stated value (which is $1.00 per share) of such share of Series L Preferred Stock
by the conversion price. The conversion price is equal to the average closing price of the Shares on the 10 trading days immediately
prior to the conversion date.
Each
holder of the Series L Preferred Stock is entitled to vote on all matters submitted to a vote of the holders of the Shares. Each
share of Series L Preferred Stock shall be entitled to the whole number of votes equal to the number of Shares into which it is
then convertible (or would be convertible, if prior to December 1, 2020). The Series L Preferred Stock shall vote with the Shares
as if they were a single class of securities. As of May 5, 2020, the shares of Series L Preferred Stock were entitled to an aggregate
of 2,500,000,000 votes.
(iii)
the 1-for-10,000 reverse stock split of the Shares effective at 5:00 p.m., Eastern time, on July 31, 2020. As a result of the
reverse stock split, every 10,000 Shares of pre-split stock were combined and reclassified into one Share. Stockholders who would
have otherwise held a fractional Share received a cash payment in respect of such fraction of a Share. All outstanding preferred
shares, stock options, warrants and equity incentive plans immediately prior to the reverse split generally were appropriately
adjusted by dividing the number of Shares into which the preferred shares, stock options, warrants and equity incentive
plans were exercisable or convertible by 10,000 and multiplying the exercise or conversion price by 10,000 as a result of the
reverse split.
CUSIP
No. 759757 88 3
|
13D
|
Page
8 of 10
|
(iv)
the Voting Agreement and Irrevocable Proxy, entered into as of August 13, 2020 (the “Voting Agreement”), among the
Issuer, Mr. Lagan, Alcimede and Christopher Diamantis, pursuant to which Mr. Diamantis granted an irrevocable proxy to Mr. Lagan
to vote the Series M Convertible Preferred Stock (the “Series M Preferred Stock”) owned by Mr. Diamantis. Mr. Diamantis
has retained all other rights under the Series M Preferred Stock.
Each
holder of the Series M Preferred Stock shall be entitled to vote on all matters submitted to a vote of the holders of the Shares.
Regardless of the number of shares of Series M Preferred Stock outstanding and so long as at least one share of Series M Preferred
Stock is outstanding, the outstanding shares of Series M Preferred Stock shall have the number of votes, in the aggregate, equal
to 51% of all votes entitled to be voted at any meeting of stockholders or action by written consent.
Item 5.
|
Interest in Securities of the Issuer
|
Item
5 is hereby amended to include the following:
(i)
As of December 23, 2019, Mr. Lagan may be deemed to beneficially own 2,500,053,384 Shares (or approximately 20.58% of the total
number of Shares then currently deemed outstanding), which consists of 53,360 Shares owned of record by Mr. Lagan and 16 stock
options owned of record by Mr. Lagan, and as to which Mr. Lagan may be deemed to have sole dispositive and voting power; and 8
Shares owned of record by Alcimede and 2,500,000,000 Shares into which the Series K Preferred Stock owned of record by Alcimede
were convertible as of December 23, 2019. Mr. Lagan may be deemed to have shared dispositive and voting power with Alcimede over
the 8 Shares owned of record by Alcimede and the 2,500,000,000 Shares into which the Series K Preferred Stock owned of record
by Alcimede were convertible as of December 23, 2019. Because the conversion price of the Series K Preferred Stock was determined
by the average closing price of the Shares for the 10 trading days immediately prior to the conversion date, the number of Shares
issuable upon conversion increased or decreased depending upon the market price of the Shares at any particular time. Such Shares
do not include 17 Shares owned of record by Epizon and with respect to such Shares, The Shanoven Trust, P. Wilhelm F. Toothe,
as trustee of The Shanoven Trust, and Epizon shared dispositive and voting power. Such Shares also do not include Shares
owned by a third party entity, and which third party entity is owned by a trust of which P. Wilhelm F. Toothe serves as trustee.
(ii)
As of May 5, 2020, Mr. Lagan may be deemed to beneficially own 53,384 Shares (or approximately 0.0% of the total number of Shares
then currently deemed outstanding), which consists of 53,360 Shares owned of record by Mr. Lagan and 16 stock options owned of
record by Mr. Lagan, and as to which Mr. Lagan may be deemed to have sole dispositive and voting power; and 8 Shares owned of
record by Alcimede. Mr. Lagan may be deemed to have shared dispositive and voting power with Alcimede over the 8 Shares owned
of record by Alcimede. Such Shares do not include 17 Shares owned of record by Epizon and with respect to such Shares, The Shanoven
Trust, P. Wilhelm F. Toothe, as trustee of The Shanoven Trust, and Epizon shared dispositive and voting power. Such Shares
also do not include Shares owned by a third party entity, and which third party entity is owned by a trust of which P. Wilhelm
F. Toothe serves as trustee. Alcimede also owned 250,000 shares of Series L Preferred Stock as of May 5, 2020. The Series L Preferred
Stock, however, is not convertible into Shares prior to December 1, 2020, although, as of May 5, 2020, the shares of Series L
Preferred Stock were entitled to an aggregate of 2,500,000,000 votes on all matters submitted to a vote of the holders of Shares,
as described above. As a result, as of May 5, 2020, Mr. Lagan and Alcimede owned securities holding 20.2% of the total voting
power of the Issuer’s voting securities. Because the conversion price of the Series L Preferred Stock is determined based
on the market price of the Shares, the number of votes to which the Series L Preferred Stock is entitled will fluctuate.
(iii)
As of 5:00 p.m., Eastern time, on July 31, 2020, Mr. Lagan may be deemed to beneficially own 11 Shares (or approximately 0.0%
of the total number of Shares then currently deemed outstanding), which consists of five Shares owned of record by Mr. Lagan and
six stock options owned of record by Mr. Lagan, and as to which Mr. Lagan may be deemed to have sole dispositive and voting power.
Alcimede also owned 250,000 shares of Series L Preferred Stock as of July 31, 2020. The Series L Preferred Stock, however, is
not convertible into Shares prior to December 1, 2020, although, as of July 31, 2020, the shares of Series L Preferred Stock were
entitled to an aggregate of 116,279 votes on all matters submitted to a vote of the holders of Shares, as described above. As
a result, as of July 31, 2020, Mr. Lagan and Alcimede owned securities holding 2.0% of the total voting power of the Issuer’s
voting securities. Because the conversion price of the Series L Preferred Stock is determined based on the market price of the
Shares, the number of votes to which the Series L Preferred Stock is entitled will fluctuate. Due to the reverse split, Mr. Lagan,
Alcimede and Epizon all received cash in lieu of their fractional shares. After the reverse split, none of Alcimede, Epizon or
The Shanoven Trust beneficially owned any Shares. All numbers in this paragraph (iii) give effect to the reverse split.
CUSIP
No. 759757 88 3
|
13D
|
Page
9 of 10
|
(iv)
As of August 13, 2020, Mr. Lagan may be deemed to beneficially own 11 Shares (or approximately 0.0% of the total number of Shares
then currently deemed outstanding), which consists of five Shares owned of record by Mr. Lagan and six stock options owned of
record by Mr. Lagan, and as to which Mr. Lagan may be deemed to have sole dispositive and voting power. Alcimede also owned 250,000
shares of Series L Preferred Stock as of August 13, 2020. The Series L Preferred Stock, however, is not convertible into Shares
prior to December 1, 2020, although, as of August 13, 2020, the shares of Series L Preferred Stock were entitled to an aggregate
of 217,391 votes on all matters submitted to a vote of the holders of Shares, as described above. In addition, Mr. Lagan has an
irrevocable proxy to vote the Series M Preferred Stock owned by Mr. Diamantis. As a result, as of August 13, 2020, Mr. Lagan and
Alcimede owned, or had the right to vote, securities holding 54.4% of the total voting power of the Issuer’s voting securities.
Because the conversion price of the Series L Preferred Stock is determined based on the market price of the Shares, the number
of votes to which the Series L Preferred Stock is entitled will fluctuate.
Item
6.
|
Contracts, Arrangements,
Understandings or Relationships with Respect to Securities of the Issuer
|
Item
6 is hereby amended to include the following:
On
August 13, 2020, Christopher Diamantis, a former director of the Issuer, entered into the Voting Agreement with the Issuer, Mr.
Lagan and Alcimede, pursuant to which Mr. Diamantis granted an irrevocable proxy to Mr. Lagan to vote the 22,000 shares of Series
M Preferred Stock owned by Mr. Diamantis. Mr. Diamantis has retained all other rights under the Series M Preferred
Stock, including the right to convert the Series M Preferred Stock into Shares. To the extent Mr. Diamantis does convert any Series
M Preferred Stock into Shares, such Shares would also be covered by the irrevocable proxy granted to Mr. Lagan.
The
foregoing description of the Voting Agreement does not purport to be complete and is qualified by reference to the Voting Agreement,
a copy of which is filed as an exhibit to this Amendment No. 7 and is incorporated herein by reference.
Item 7.
|
Materials to be Filed as Exhibits
|
Item
7 is hereby amended to include the following:
Exhibit 99.1 – Joint Filing Agreement pursuant to Rule 13d-1(k).*
Exhibit 99.2 – Voting Agreement and Irrevocable Proxy, dated as of August 13, 2020, by and among Rennova Health, Inc., Seamus Lagan, Alcimede LLC and Christopher Diamantis (incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2020).
*
Filed herewith
CUSIP
No. 759757 88 3
|
13D
|
Page
10 of 10
|
SIGNATURES
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
August
26, 2020
|
/s/ Seamus Lagan
|
|
Seamus Lagan, individually
|
|
|
|
August
26, 2020
|
Alcimede
LLC
|
|
|
|
|
By:
|
/s/
Seamus Lagan
|
|
|
Seamus
Lagan, Sole Manager
|
|
|
|
August
26, 2020
|
Epizon
Ltd.
|
|
|
|
|
By:
|
The
Shanoven Trust
|
|
|
|
|
By:
|
/s/
P. Wilhelm F. Toothe
|
|
|
P.
Wilhelm F. Toothe, Trustee
|
|
|
|
August
26, 2020
|
The
Shanoven Trust
|
|
|
|
|
By:
|
/s/
P. Wilhelm F. Toothe
|
|
|
P.
Wilhelm F. Toothe, Trustee
|